Skip to content. | Skip to navigation

Personal tools


Managing bodies

logo Inserm      logo cnrslogo ENSL       logo ucb1

Secondary managing bodies

logo ENSL logo ucb1

You are here: Home / About us / News / Launch of the Chaire industrielle REVIDA

Launch of the Chaire industrielle REVIDA

On october 11, the Chaire industrielle REVIDA about respiratory infectious diseases, led by the researcher Sophie Trouillet-Assant (UCBL/HCL), was officially launched by the Université Claude Bernard Lyon 1, the Hospices Civils de Lyon, and bioMérieux, with the support of the Agence nationale de la recherche. It should enable the improvement of the capacity of health systems to face the emerging of new respiratory diseases.

The COVID-19 pandemic showed the devastating impact of an unknown infectious disease. The lack of prevention tools and of treatments worsened the crisis. Three years later, the cost to our society is high, with repercussions all over the world.

Now more than ever, the consequences of the mergence of new viruses, particularly respiratory viruses, is a major public health concern. The emergence of viral diseases is set to accelerate, partly due to climate change. 

It is with the idea of better facing these potential emerging viruses that the "chaire industrielle" REVIDA (infections REspiratoires VIrales - du DiAgnostic au Pronostic / viral respiratory infections - from diagnosis to prognosis) was formed, led by Dr Sophie Trouillet-Assant (UCBL/HCL).

Hosted by the Université Claude Bernard Lyon 1 and working in the mixed laboratory HCL/UCBL/bioMérieux, she will combine the work from the Centre international de recherche en infectiologie (CIRI – CNRS/Inserm/Université Claude Bernard Lyon 1/ENS de Lyon), the Hospices Civils de Lyon and from bioMérieux to offer new - efficient and innovating - diagnosis solutions, which will improve management of patients suffering from respiratory infections.

The goal is to identify more quickly the people suffering from viral infections, no matter the virus, in order to react faster if a new pandemic were to happen and to be able to quickly predict who would be particularly likely to develop a severe form of the disease, and thus improve management of patients.

Dans cette optique, le projet ambitieux et innovant de la chaire REVIDA étudiera la réponse immunitaire des patients infectés pour mettre au point de nouveaux outils diagnostiques et pronostiques rapides des infections virales respiratoires sans recherche systématique de l’agent pathogène.

With this in mind, the ambitious and innovative project of the REVIDA chaire will study the immune response of infected patients to design new diagnosis and prognosis tools able to quickly detect viral respiratory infections without having to look for the specific pathogen.


You can find out more in the whole press release here.


You can also find this news on the websites of the Université Claude Bernard Lyon 1 and the Université Claude Bernard Lyon 1

Text (french version) : Béatrice DIAS, Directrice de la communication de l'Université Claude Bernard Lyon 1


Lead image : Launch of the chaire Revida, from left to right : Jérôme Honnorat, Vice-président recherche délégué secteur "Santé" de l’UCBL, Ilias Iliopoulos, président référent du comité « chaires industrielles » de l’ANR, Frédéric Fleury, président de l’Université Claude Bernard Lyon 1, Aurore Fleurie, Senior Manager R&D bioMérieux, Coresponsable de l’unité mixte HCL-UCBL-bioMérieux, Sophie Trouillet-Assant, chercheuse au CIRI, responsable de l’unité mixte HCL-UCBL-bioMérieux, Alexandre Pachot, Directeur de la Recherche en Santé chez HCL, François Lacoste, Directeur Exécutif Recherche & Développement chez bioMérieux, Bruno Lina, chef de service laboratoire de virologie, directeur du CNR des virus respiratoires, François-Loic Cosset, directeur du CIRI 

Filed under: